- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more
Location Directory
Clinical trials in Dallas, Texas
This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13791
Shown on this page
12
Current sort
Recently updated
Location scope
Dallas, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 421–432 of 13,791 matching trials in Dallas, TX.
Live ClinicalTrials.gov results.
Institutions in Dallas
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
- Device · Drug
- Lead sponsor
- CarThera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 14,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 241
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
- Conditions
- Parkinson's Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
- Conditions
- Diabetic Gastroparesis
- Interventions
- CIN-102 Dose 15mg or 10mg, Placebo
- Drug
- Lead sponsor
- CinDome Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 100
- States / cities
- Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
- Behavioral · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
- Conditions
- Focal Epilepsy
- Interventions
- XEN1101
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
- Interventions
- CardioMEMS HF System, HeartMate 3 Left Ventricular Assist System, Guideline Medical Directed Therapy
- Device · Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 52 more
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 13
- States / cities
- La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- PF-08052667, Sasanlimab, BCG, PF-02921367
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Botensilimab, Balstilimab, Standard of Care
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
- Interventions
- Thor laser atherectomy
- Device
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- St. Helena, California • Aurora, Colorado • Bradenton, Florida + 24 more